Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$49.84 USD

49.84
6,013,326

-4.24 (-7.84%)

Updated May 24, 2024 04:00 PM ET

After-Market: $49.85 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for EXAS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Exact Sciences Corporation [EXAS]

Reports for Purchase

Showing records 121 - 140 ( 364 total )

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 121

10/27/2016

Company Report

Pages: 7

3Q Tops Expectations as 2016 Volume Guidance Reaffirmed

Provider: Roth Capital Partners, Inc.

Analyst: LEWIS C

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 122

10/27/2016

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 123

10/07/2016

Industry Report

Pages: 11

Sector Analysis Update: Molecular Diagnostics: Does the Turnaround have ''''Legs''''?

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: GRISEWOOD S

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 124

10/07/2016

Company Report

Pages: 4

Dropping Coverage Due to Analyst Departure

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 125

07/27/2016

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 126

07/27/2016

Company Report

Pages: 6

2Q Beat, Unchanged 2016 Outlook Still Back-End Heavy

Provider: Roth Capital Partners, Inc.

Analyst: LEWIS C

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 127

06/17/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 128

06/17/2016

Company Report

Pages: 6

Cologuard Included in Final USPSTF CRC Guidelines

Provider: Roth Capital Partners, Inc.

Analyst: LEWIS C

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 129

06/15/2016

Company Report

Pages: 5

Leaked JAMA Article Indicates Potentially Positive USPSTF Development

Provider: Roth Capital Partners, Inc.

Analyst: LEWIS C

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 130

06/15/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 131

05/04/2016

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 132

05/03/2016

Company Report

Pages: 7

1Q Inline, 2016 Outlook Reaffirmed but Implies Significant 2H16 Ramp

Provider: Roth Capital Partners, Inc.

Analyst: LEWIS C

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 133

02/25/2016

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 134

02/25/2016

Company Report

Pages: 8

Downgrading to Neutral on 2016 Outlook Viability

Provider: Roth Capital Partners, Inc.

Analyst: LEWIS C

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 135

01/05/2016

Industry Report

Pages: 2

Med Tech Preannouncement Watch - Look for News into Next Week?s JPM Conference

Provider: Roth Capital Partners, Inc.

Analyst: LEWIS C

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 136

10/30/2015

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 137

10/30/2015

Company Report

Pages: 6

Reset Expectations w/ Light 2016 Guide; USPSTF Uncertainties Linger

Provider: Roth Capital Partners, Inc.

Analyst: LEWIS C

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 138

10/29/2015

Company Report

Pages: 9

Pre-call Summary - Test Volume Looked Above Street - Just Below Wedbush - GMs Better - Offset By Worse Opex - No Guidance - Maintain N

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 139

10/29/2015

Company Report

Pages: 10

3Q15 Recap - Volume Ok - 4Q - 2016 Guidance Soft - GMs Better - Offset By Worse Opex - Lowering PT to $6.50 - Maintain NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 140

10/23/2015

Company Report

Pages: 9

Expecting Slightly Better 3Q15 Volume - Sales - Private Payor Discussions - Cologuard Ramp Key - Maintain N

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party